The occurrence of drug-induced side effects in women and men with arterial hypertension and comorbidities.

Kardiol Pol

Centro PASCIA (Programma Assistenziale Scompenso cardiaco, Cardiopatie dell'Infanzia e A rischio), Modena, Italy.

Published: December 2022

Download full-text PDF

Source
http://dx.doi.org/10.33963/KP.a2022.0233DOI Listing

Publication Analysis

Top Keywords

occurrence drug-induced
4
drug-induced side
4
side effects
4
effects women
4
women men
4
men arterial
4
arterial hypertension
4
hypertension comorbidities
4
occurrence
1
side
1

Similar Publications

Background: Drug-induced thrombocytopenia (DITP) often occurs in patients during clinical treatment. However, clinicians usually fail to distinguish which drugs can be plausible culprits accurately. We aimed to develop a large comprehensive drug benchmark database with DITP toxicity using the recommended method by FDA.

View Article and Find Full Text PDF

Background: Occurrence of life-threatening scorpion sting in adults is a rare entity compared with children. Different cases of organ failure following scorpion sting have been reported but complications, such as acute toxic myocarditis, cardiogenic shock, pulmonary edema, acute kidney injury and toxic hepatitis occurring simultaneously in adult patients is exceedingly rare with no prior documented similar report. This case report explores the unique presentation of these complications occurring simultaneously and their management in resource limited setting.

View Article and Find Full Text PDF

Background: Drug-induced acute pancreatitis is a rare condition occurs at an incidence rate of 0.1-1.4% and represents a diagnostic challenge.

View Article and Find Full Text PDF

Hepatobiliary Adverse Events Associated With the KRAS p.G12C Inhibitor Sotorasib.

Pharmacoepidemiol Drug Saf

February 2025

Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

Purpose: The p.G12C mutation in KRAS is commonly found in many cancers and was previously untreatable until drugs like sotorasib were developed. However, up to 15% of patients treated with sotorasib have experienced hepatobiliary adverse events.

View Article and Find Full Text PDF

Mapping the effectiveness and risks of GLP-1 receptor agonists.

Nat Med

January 2025

Clinical Epidemiology Center, Research and Development Service, VA St. Louis Health Care System, St. Louis, MO, USA.

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are increasingly being used to treat diabetes and obesity. However, their effectiveness and risks have not yet been systematically evaluated in a comprehensive set of possible health outcomes. Here, we used the US Department of Veterans Affairs databases to build a cohort of people with diabetes who initiated GLP-1RA (n = 215,970) and compared them to those who initiated sulfonylureas (n = 159,465), dipeptidyl peptidase 4 (DPP4) inhibitors (n = 117,989) or sodium-glucose cotransporter-2 (SGLT2) inhibitors (n = 258,614), a control group composed of an equal proportion of individuals initiating sulfonylureas, DPP4 inhibitors and SGLT2 inhibitors (n = 536,068), and a control group of 1,203,097 individuals who continued use of non-GLP-1RA antihyperglycemics (usual care).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!